STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir (STO:MVIRB) has today announced that the licensing rights for MIV-210 have reverted to Medivir from Tibotec Pharmaceuticals Ltd.
In previously performed pre-clinical trials, MIV-210 has demonstrated very potent activity against Hepatitis B Virus (HBV) and has good pharmacokinetic properties.
